International Conference on

Clinical & Experimental Dermatology, Plastic Surgery

September 17, 2021 | Webinar

Emerging Tests Will Reveal a Patient's Personal Level of Risk in five, 10, or 20 Years for Specific and Increasingly Rare Skin Conditions - Will We Be Ready?

Jack Ray Gallagher

Clarity Pharma Research LLC, USA

Biological science is advancing knowledge of the human body at an explosive rate because of continually improving technological tools such as artificial intelligence (AI), nanotechnology, 3D printing, quantum computing, and joint collaborative efforts of scientists around the world. The most ambitious and potentially consequential global collaborative effort is the Human Cell Atlas (HCA) project involving more than 10,000 scientists from more than 100 countries. These scientists are working together to accomplish many vital objectives, including identifying and classifying all 37.2 trillion cells of the human body (average person), of which more than 4 trillion are skin cells. They seek to gain a deeper understanding of the way in which tissues and organs are constructed, to determine the level to which genes are activated in each type of cell, quantify how many copies of each protein is present, determine which cells go wrong in a specific disease, and contribute to the betterment of humankind. According to Daniel M. Davis, one of the world's leading contributors to immune-system science, this HCA-created sea of information not only will address our present medical conditions, but also contain results of more advanced metrics showing our personal probability of acquiring specific new illnesses in five, 10 or 20 years. How will people deal with possible future threatening skin conditions? A plethora of charts, graphs, written explanations of scientific studies, and other intended aids will be provided to help explain one's personal future disease probabilities. Many people, however, undoubtedly will turn to a trusted physician for explanation of this maze of data and for guidance on how best to weigh and prioritize needed current actions to prevent or reduce the chances of developing a dreaded disease in the near and distant future.

Conclusion: Dermatologists, as well as other physicians, must start now to prepare for this expanded, complex, and critical patient-assistance role. This presentation will help dermatologists and plastic surgeons understand the magnitude and dimensions of risk theory and demonstrate how to use a powerful analytical and educational tool to help clarify and properly guide individual patients: a risk matrix.

Biography

Dr. Gallagher, founder and chief scientist at Clarity Pharma Research, LLC, is an internationally recognized medical/healthcare researcher/scientific conference presenter, futurist, an editor of Current Trends in Clinical & Medical Sciences and an expert reviewer for Journal of Chemotherapy. His paper on future challenges presented at the Second International Conference on Marketing and Development in Budapest won first place, and the OncLive interview about his presentation at the European Society for Medical Oncology Congress 2018 (Munich) was distributed worldwide and published in Future Oncology (Dec. 2019). He co-chaired the sessions on gynecological oncology at the PCS 4th Global OB/GYN 2019 Congress (Prague). He is a mathematician and doctorate-level clinical psychologist who formerly directed a multi-university research consortium while on the faculty of the University of Virginia School of Medicine. He invented a remote-control guidance system for blind athletes and was also a former Virginia decathlon submasters record holder for 10 years.